Deals

Florida SBA explores multibillion-dollar portfolio sale

The pension has been actively pursuing opportunities in the secondaries market over the past few years.

CVC emerges as lead in Cerberus’s large CV for SubCom

The deal marks the latest $1bn-plus CV the Luxembourg-headquartered firm has been involved in over the last several months.

Hayfin anchors €155m Spanish healthcare CV

Spanish manager Alantra has closed a continuation vehicle for its portfolio company Health in Code, with 25% of the capital earmarked for follow on investment.

Coller leads on $1.3bn Ares credit continuation vehicle

The firm, which EQT recently agreed to acquire, has led on multiple multibillion-dollar credit CVs over the past several months.

DW Healthcare runs process to extend hold over animal pharmaceuticals business

While some participants have described secondaries activity as somewhat subdued in the early part of the year, numerous deals continue to work through their processes that had been launched last year.

Lexington and Partners Group among buyers on CalPERS’ latest LP-led sale

The original size of the portfolio CalPERS brought to the market is understood to be between $2.3bn and $3bn.

Eurazeo and Pantheon complete €480m credit CV

The deal is the second between the two firms to provide liquidity to Eurazeo’s LPs while maintaining continuity for borrowers.

Managers increasingly look to fill secondaries gaps with GP acquisitions – Campbell Lutyens

As more high-profile secondaries managers get snapped up, there is a ‘scarcity value’ in the strategy, managing director Hannah Gore-Randall tells Secondaries Investor.

ILPA template aims to cut CV deal hassles

The new questionnaire asks GPs to disclose details including transaction terms and asset returns.

EQT unveils continuation fund for EdgeConnex

EQT has set up an open ended structure for EdgeConnex to support the data centre platform’s long-term growth opportunity, head of business development Gustav Segerberg said on the firm’s full-year 2025 earnings call.